As of 2024-12-15, the Relative Valuation of BioMark Diagnostics Inc (BUX.CN) is (0.01) CAD. This relative valuation is based on P/E multiples. With the latest stock price at 0.23 CAD, the upside of BioMark Diagnostics Inc based on Relative Valuation is -106.4%.
The range of the Relative Valuation is (0.01) - (0.11) CAD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 0.7x - 6.9x | 0.9x |
| Forward P/E multiples | 0.6x - 6.3x | 0.7x |
| Fair Price | (0.01) - (0.11) | (0.01) |
| Upside | -105.7% - -150.4% | -106.4% |
| Date | P/E |
| 2024-11-29 | -12.53 |
| 2024-11-28 | -12.53 |
| 2024-11-27 | -11.97 |
| 2024-11-25 | -11.70 |
| 2024-11-22 | -11.42 |
| 2024-11-21 | -10.03 |
| 2024-11-18 | -12.25 |
| 2024-11-15 | -12.81 |
| 2024-11-11 | -13.65 |
| 2024-11-08 | -12.81 |
| 2024-11-06 | -12.81 |
| 2024-11-05 | -12.81 |
| 2024-11-04 | -13.09 |
| 2024-11-01 | -13.09 |
| 2024-10-25 | -13.37 |
| 2024-10-24 | -13.37 |
| 2024-10-22 | -13.37 |
| 2024-10-10 | -13.65 |
| 2024-10-09 | -13.37 |
| 2024-10-08 | -12.81 |
| 2024-10-03 | -13.92 |
| 2024-09-30 | -13.92 |
| 2024-09-19 | -14.48 |
| 2024-09-18 | -13.65 |
| 2024-09-17 | -13.37 |
| 2024-09-10 | -13.92 |
| 2024-09-05 | -13.37 |
| 2024-09-04 | -13.92 |
| 2024-09-03 | -12.25 |